A surveillance study was undertaken to identify prominent β-lactamase encoding genes in 131 carbapenem non-susceptible gram-negative clinical isolates at a New York City community hospital. KPC carbapenemases were detected in 89% of Enterobacteriaceae as well as additional TEM, SHV, and CTX-M class A enzymes. OXA-23 and OXA-24 were the prevalent class D carbapenemases identified in Acinetobacter species. One OXA-23 in M. morganii and one OXA-48 in K. pneumoniae were also identified. Among class C β-lactamases CMY, ACT/MIR, DHA, and FOX were detected. The in vitro activity of ceftazidime-avibactam by E-test methodology was tested with minimal inhibitory concentrations (MIC) of ≤3 µg/ml for 97.8% of all Enterobacteriaceae, MIC 50/90 of 16/>256 µg/ml for carbapenem non-susceptible Acinetobacter, and 3/6 µg/ml for carbapenem non-susceptible Pseudomonas aeruginosa. Periodic surveillance of isolates to characterize current and emerging β-lactamase genotypes present in local isolates may help identify outbreak situations, provide assistance to infection control and antibiotic stewardship programs, and potentially improve patient outcomes.
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Introduction
Carbapenem resistant Enterobacteriaceae (CRE), MDR Pseudomonas aeruginosa (MDRPSA) and MDR Acinetobacter (MDRAC) are urgent and serious threats as designated by the Centers for Disease Control and Prevention (CDC) [1] . Phenotypic expression of carbapenem resistance (reported by many clinical microbiology laboratories) can be due to numerous mechanisms with β-lactam hydrolyzing enzymes being the major contributor [2] . Therefore, it is important to classify which enzyme(s) is (are) present since detection is a vital component in defining their epidemiology, controlling spread, as well as aiding appropriate early therapeutic interventions. Since our hospital has a long history of β-lactam resistance present in multi-drug resistant gram-negative bacteria, an investigation was undertaken to characterize current enzymes associated with carbapenem resistant gram-negative bacteria. We also assessed the in vitro activity of ceftazidime-avibactam (CA), which has been shown to inhibit a wide spectrum of β-lactamase producing organisms, including those with KPC enzymes.
Materials and Methods

Microbiology and Susceptibility
One-hundred and thirty-one carbapenem non-susceptible gram-negative single-patient clinical isolates from blood, urine, sputum, and stool were identified in our Clinical Microbiology Laboratory using the Vitek 2® GN (gram-negative) ID card (bioMerieux, Durham, NC). Isolates identified from community and hospitalized patients as well as residents of an affiliated long-term care facility (LTCF) were selected from January 2012 through December 2015. Of these, 87 were Enterobacteriaceae consisting of 9 Citrobacter species, 29 Escherichia coli, 27 Enterobacter species, 13 Klebsiella pneumoniae, 8 Serratia marcescens and 1 Morganella morganii; 44 were non-fermenters which included 24 carbapenem non-susceptible Pseudomonas aeruginosa and 20 carbapenem non-susceptible Acinetobacter. Susceptibility to CA by E-test methodology was performed according to the manufacturer's specifications (bioMerieux, Durham, NC).
Klebsiella pneumoniae ATCC 700603 was tested against CA and ceftazidime alone by E-test methodology to confirm the activity of avibactam.
DNA Isolation and Amplification
Bacteria were grown overnight on TSA II 5% blood agar plates and DNA was extracted from colonies using the DNeasy® blood and tissue kit (Qiagen Sciences, Germantown, MD). The Check-MDR CT103 XL microarray system was used for detection of β-lactamases according to manufacturer's instructions (Check points, Wegeningen, Netherlands). A description of the microarray technology and β-lactamases that can be detected has been described in detail [3] and plasmid-mediated AMP-C (1/29, 3% ACT/MIR and 1/29, 3% CMY) enzymes were documented. K. pneumoniae isolates harbored TEM (9/13, 69%), SHV (12/13, 92%), CTX-M (5/13, 38%), OXA-48 (1/13, 8%), and ESBLs (5/13, 38%) β-lactamases. In Citrobacter isolates, enzymes detected were TEM (7/9, 78%), SHV (2/9, 22%), ESBLs (2/9, 22%), and plasmid-mediated AMP-C (2/9, 22% ACT/MIR and 1/9, 11% CMY). In Enterobacter species, 10/27 (37%) harbored ESBLs and 20/27 (74%) possessed plasmid mediated β-lactamases including ACT/MIR (17/27, 63%), DHA (2/27, 7%) and FOX (1/27, 4% No NDM, VIM, IMP, GIM or SPM metallo-β-lactamases were identified in any of the isolates. Pseudomonas aeruginosa (24) 3/24 1/24
Minimal Inhibitory Concentration of Ceftazidime and Ceftazidime-Avibactam by E-Test Methodology
Minimal inhibitory concentration (MIC) for CA by E-test ( of 12 µg/ml/24µg/ml for ceftazidime, 3 µg/ml/6µg/ml for CA and >256/>256, 16/>256 µg/ml for carbapenem non-susceptible Acinetobacter respectively, were recorded.
Discussion
In this surveillance study designed to identify current β-lactamases in a New York City hospital, KPC β-lactamases were the predominant enzymes characterized in carbapenem non-susceptible Enterobacteriaceae and reinforces our previously published studies recognizing such enzymes in hospitalized and community patients and in residents of our associated LTCF [6] Klebsiella pneumoniae (13) 64 Check MDR microarray systems or other commercially available systems. These enzymes are not inhibited by any current β-lactamase inhibitors, including avibactam. This is delineated in Table 2 with no difference in MICs (3 µg/ml) between ceftazidime alone and CA. This is in contrast to the OXA-48 enzyme found in K. pneumoniae which is inhibited by avibactam, (MIC for ceftazidime = 128 µg/ml, MIC for CA = 0.75 µg/ml). Among Acinetobacter isolates, OXA-23 and OXA-24 were the predominant carbapenemases, a finding consistent with our earlier studies [16] [17] . While all P. aeruginosa in this study were reported as carbapenem resistant by the Vitek 2® system, the Check-MDR CT103 XL Microarray reported no carbapenem resistant genotypes likely due to lack of specific ampC primers for Pseudomonas aeruginosa. To our knowledge, no commercial system is available to detect such enzymes.
Carbapenem resistance in Pseudomonas aeruginosa can be due to the interplay of up regulated efflux, chromosomal ampC β-lactamase production, and diminished oprD [18] . Thus, both phenotypic and genotypic testing may be necessary for better prediction of antibacterial resistance and opportunity for better directed therapy in these and additional isolates expressing these determinants.
An earlier study evaluating the in vitro activity of CA against all Enterobacteriaceae isolates from US hospitals with characterization of associated β-lactamases, documented MIC 50/90 of 0.12/0.25 µg/ml for CA [19] . In contrast, we found MIC 50/90 of 0.5/ 1.5µg/ml for carbapenem non-susceptible strains. Another survey, which also characterized such isolates and their susceptibility to CA, reported MIC 50/90 , of 1/1µg/ml [20] . Although not assessed in our study, elevated MICs have been associated with KPC-3 strains of K. pneumoniae as well as strains with ESBLs and porin mutations and this is an area for future investigation [21] .
We have previously used other molecular techniques to characterize β-lactamase encoding genes in 24% of the isolates analyzed in this study [7] [8] [22] [23] LaBombardi VJ, unpublished results]. However, recent studies have demonstrated sensitivities and specificities of 100% and accuracies of 94% for the detection of known resistance genes using the Check-Points MDR CT103 XL microarray kit (4, 5) .
In conclusion, we have identified class A, C and D β-lactamase encoding genes in carbapenem non-susceptible gram-negative clinical isolates at our community hospital in New York City. Molecular characterization in conjunction with phenotypic reporting by clinical microbiology laboratories can provide a "snapshot" of enzymes present within a geographical area, can support antibiogram data and reveal β-lactamases that are "silently disseminating" [24] [25] . Genotypic results from systems such as the one used in this study may answer the question: "are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?" [26] . Periodic sampling such as this may be beneficial to describe epidemiologic evolution of carbapenem resistant organisms. Combining phenotypic and genotypic data has significant potential for identifying unrecognized reservoirs in both hospital and LTCFs, can be instrumental in detecting outbreaks, and provide assistance to infection control and antibiotic stewardship programs which can potentially improve patient outcomes.
